Sepp-Lorenzino Laura has filed 21 insider transactions across 2 companies since January 2023.
Most recent transaction: a grant/award of 113246 shares of Taysha Gene Therapies, Inc. ($TSHA) on June 02, 2025.
Activity breakdown: 0 open-market purchases and 7 sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| June 2, 2025 | Taysha Gene Therapies, Inc. | $TSHA | Sepp-Lorenzino Laura | Not found | A | Stock Option (right to buy) | 113246 | $0.00 | 113,246.0000 | 250,134,421 | 9999.99% | 0.05% |
| June 2, 2025 | Taysha Gene Therapies, Inc. | $TSHA | Sepp-Lorenzino Laura | Not found | A | Common Stock | 56623 | $0.00 | 105,843.0000 | 250,134,421 | 115.04% | 0.02% |
| Jan. 3, 2025 | Intellia Therapeutics, Inc. | $NTLA | Sepp-Lorenzino Laura | EVP, Chief Scientific Officer | S | Common Stock | 8966 | $12.18 | 77,388.0000 | 0 | 10.38% | 0.00% |
| Jan. 1, 2025 | Intellia Therapeutics, Inc. | $NTLA | Sepp-Lorenzino Laura | EVP, Chief Scientific Officer | M | Common Stock | 3500 | $0.00 | 86,354.0000 | 0 | 4.22% | 0.00% |
| Jan. 1, 2025 | Intellia Therapeutics, Inc. | $NTLA | Sepp-Lorenzino Laura | EVP, Chief Scientific Officer | M | Restricted Stock Unit | 3500 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| May 29, 2024 | Taysha Gene Therapies, Inc. | $TSHA | Sepp-Lorenzino Laura | Not found | A | Stock Option (right to buy) | 98440 | $0.00 | 98,440.0000 | 116,121,482 | 9999.99% | 0.08% |
| May 29, 2024 | Taysha Gene Therapies, Inc. | $TSHA | Sepp-Lorenzino Laura | Not found | A | Common Stock | 49220 | $0.00 | 49,220.0000 | 116,121,482 | 9999.99% | 0.04% |
| March 1, 2024 | Intellia Therapeutics, Inc. | $NTLA | Sepp-Lorenzino Laura | EVP, Chief Scientific Officer | A | Common Stock | 37966 | $0.00 | 81,893.0000 | 0 | 86.43% | 0.00% |
| March 1, 2024 | Intellia Therapeutics, Inc. | $NTLA | Sepp-Lorenzino Laura | EVP, Chief Scientific Officer | A | Stock Option (right to buy) | 54794 | $0.00 | 54,794.0000 | 0 | 9999.99% | 0.00% |
| Jan. 8, 2024 | Intellia Therapeutics, Inc. | $NTLA | Sepp-Lorenzino Laura | EVP, Chief Scientific Officer | S | Common Stock | 667 | $29.38 | 43,927.0000 | 0 | 1.50% | 0.00% |
| Jan. 8, 2024 | Intellia Therapeutics, Inc. | $NTLA | Sepp-Lorenzino Laura | EVP, Chief Scientific Officer | S | Common Stock | 1608 | $28.66 | 44,594.0000 | 0 | 3.48% | 0.00% |
| Jan. 3, 2024 | Intellia Therapeutics, Inc. | $NTLA | Sepp-Lorenzino Laura | EVP, Chief Scientific Officer | S | Common Stock | 5532 | $29.46 | 46,202.0000 | 0 | 10.69% | 0.00% |
| Jan. 1, 2024 | Intellia Therapeutics, Inc. | $NTLA | Sepp-Lorenzino Laura | EVP, Chief Scientific Officer | M | Common Stock | 3500 | $0.00 | 51,734.0000 | 0 | 7.26% | 0.00% |
| Jan. 1, 2024 | Intellia Therapeutics, Inc. | $NTLA | Sepp-Lorenzino Laura | EVP, Chief Scientific Officer | M | Restricted Stock Unit | 3500 | $0.00 | 3,500.0000 | 0 | 50.00% | 0.00% |
| March 1, 2023 | Intellia Therapeutics, Inc. | $NTLA | Sepp-Lorenzino Laura | EVP, Chief Scientific Officer | A | Common Stock | 29938 | $0.00 | 47,567.0000 | 0 | 169.82% | 0.00% |
| March 1, 2023 | Intellia Therapeutics, Inc. | $NTLA | Sepp-Lorenzino Laura | EVP, Chief Scientific Officer | A | Stock Option (right to buy) | 42302 | $0.00 | 42,302.0000 | 0 | 9999.99% | 0.00% |
| Jan. 4, 2023 | Intellia Therapeutics, Inc. | $NTLA | Sepp-Lorenzino Laura | EVP, Chief Scientific Officer | S | Common Stock | 2508 | $37.21 | 19,959.0000 | 0 | 11.16% | 0.00% |
| Jan. 5, 2023 | Intellia Therapeutics, Inc. | $NTLA | Sepp-Lorenzino Laura | EVP, Chief Scientific Officer | S | Common Stock | 1641 | $38.22 | 18,318.0000 | 0 | 8.22% | 0.00% |
| Jan. 5, 2023 | Intellia Therapeutics, Inc. | $NTLA | Sepp-Lorenzino Laura | EVP, Chief Scientific Officer | S | Common Stock | 689 | $39.10 | 17,629.0000 | 0 | 3.76% | 0.00% |
| Jan. 1, 2023 | Intellia Therapeutics, Inc. | $NTLA | Sepp-Lorenzino Laura | EVP, Chief Scientific Officer | M | Common Stock | 3500 | $0.00 | 22,467.0000 | 0 | 18.45% | 0.00% |
| Jan. 1, 2023 | Intellia Therapeutics, Inc. | $NTLA | Sepp-Lorenzino Laura | EVP, Chief Scientific Officer | M | Restricted Stock Unit | 3500 | $0.00 | 7,000.0000 | 0 | 33.33% | 0.00% |